Could an antifungal pill guard the kidneys during heart surgery?

NCT ID NCT07738328

Not yet recruiting Prevention Sponsor: Guangdong Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests whether terbinafine, a common antifungal drug, can prevent acute kidney injury in adults undergoing heart surgery with a heart-lung machine. Participants at high risk of kidney damage will receive terbinafine or a placebo before and after surgery. The study tracks kidney function for a week and monitors for complications over 30 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Terbinafine, an antifungal drug being repurposed for its antioxidant and anti-inflammatory effects
What this could lead to: If effective, terbinafine could offer a simple, low-cost way to protect kidney function in people undergoing heart surgery, reducing complications and hospital stays.
What could go wrong: This is an early-phase trial, so the drug may not prove effective or safe for this new use. Results from this 208-patient study will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY CARDIAC SURGICAL PROCEDURES

Contacts and locations

Locations

Department of Kidney Transplantation, Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.